Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Table S6. Associations between SMI and length of prior treatment exposure before starting ICB among the 144 patients that received ICB in the second+ line setting Table S7. The prevalence of SMI by the number of prior treatments received before starting ICB among the 144 patients that received ICB in the second+ line setting Table S8. Characteristics of the TCGA cohort used for gene expression analysis by SMI